World’s 1st Nanomedicine CDMO & Clinical-Phase Fill-Finish CMO. We develop and scale nanoparticle drug substance, and fill clinical-phase batches in a purpose-built sterile suite aligned with the current EU GMP Annex 1 — one partner, one hand-off avoided.
Services: Nanoparticle Drug Substance CDMO / Aseptic Fill-Finish Drug Product CMO
2F, 20 Seongsui-ro 7-gil
Seongdong-gu
Seoul, 04781
Korea
+82-2-741-6110
www.omniparticles.com
Nanotechnology Company Directory
